Back to Search
Start Over
Survival analysis for patients with metachronous contralateral breast cancer: Insights from a retrospective study.
- Source :
-
Oncology letters [Oncol Lett] 2024 Jun 21; Vol. 28 (2), pp. 390. Date of Electronic Publication: 2024 Jun 21 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Continued advances in the diagnosis and treatment of breast cancer (BC) have led to an increase in the number of long-term BC survivors and an increase in the incidence of metachronous BC in the contralateral breast. Therefore, it is important to understand the factors that influence the development of metachronous BC; however, the impact of the laterality of the initial ipsilateral (I)BC as a risk factor for the development of metachronous contralateral (MC)BC has not been extensively investigated. The present study included 17,082 female patients with stage 0-3 IBC from the prospectively maintained Korean Breast Cancer Registry from 1989-2013 and divided them into two groups: Patients with MCBC (n=88) and those without MCBC (n=16,994). Risk factors that present at the initial BC diagnosis that could significantly influence the development of MCBC were screened for and risks were evaluated using the Fine-Gray subdistribution hazard model. Significant differences in baseline characteristics between MCBC and non-MCBC groups were demonstrated. Patients aged <40 years, those with histological and nuclear grade 3 tumors, and those with the triple-negative BC subtype were significantly more prevalent in the MCBC group than in the non-MCBC group. Additionally, the cumulative incidence of MCBC increased over time, with a notable increase from 0.1% in year 1 to 1.6% in year 10. Survival analysis revealed no significant differences in overall or BC-specific survival between the two groups. Key predictive factors identified for MCBC included an age of <40 years at initial diagnosis, a negative progesterone receptor status, and a Ki-67 score of >14%. Overall, the present study revealed several factors associated with MCBC and emphasized the need for long-term monitoring of BC survivors, considering these newly identified risk factors.<br />Competing Interests: The authors declare that they have no competing interests.<br /> (Copyright: © 2024 Park et al.)
Details
- Language :
- English
- ISSN :
- 1792-1082
- Volume :
- 28
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Oncology letters
- Publication Type :
- Academic Journal
- Accession number :
- 38966583
- Full Text :
- https://doi.org/10.3892/ol.2024.14523